Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | TRHR | P34981 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14543240 | 0.87 | TRHR (0.40) | L3MBTL1POLBHDAC3HDAC1HDAC10 | |
| SCHEMBL12250668 | 0.85 | TRHR (0.41) | HDAC3HDAC1HDAC10HDAC11HDAC8 | |
| SCHEMBL12228303 | 0.82 | TRHR (0.56) | TRHR | |
| SCHEMBL14468464 | 0.81 | TRHR (0.38) | L3MBTL1TRHR | |
| SCHEMBL14543010 | 0.81 | HDAC3 (0.37) | L3MBTL1HDAC3HDAC1HDAC10HDAC11 | |
| SCHEMBL14468379 | 0.79 | POLB (0.45) | L3MBTL1POLB | |
| SCHEMBL14468460 | 0.78 | BCHE (0.53) | — | |
| SCHEMBL14543241 | 0.76 | ITGB1 (0.35) | HDAC3HDAC1HDAC6 | |
| SCHEMBL14185774 | 0.72 | TRHR (0.55) | TRHR | |
| SCHEMBL12228300 | 0.72 | TRHR (0.57) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161640-A1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | KOZIKOWSKI ALAN P | 2007-07-12 | — | — | US | disclosed |
| US-7202279-B1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | GEORGETOWN UNIVERSITY (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161640-A1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | BDNF, PMP22, ADAM17 | L3MBTL1 2750/4885POLB 4614/4885HDAC3 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.